Top 25 Independent Nursing Home Labs

by Jondavid Klipp | Nov 15, 2019 | Nursing Home

Top 25 Independent Nursing Home Labs

There are approximately 75 independent lab companies across the United States that are focused on the nursing home market. The table below lists the top 25 companies as measured by their volume of Part B services for G0471 in 2017 (the latest year of available data). G0471 is the billing code used exclusively for blood draws taken from nursing home and home health patients.

On a consolidated basis, TridentUSA Health Services is the largest nursing home lab with combined volume of 956,153 for G0471 at five lab subsidiaries in 2017. Its total Part B payments for all testing services was $50 million in 2017.

American Health Associates (Miramar, FL) is next with volume of 851,305 for G0471 and total Part B payments of $38 million in 2017.

Gamma Healthcare (Poplar Bluff, MO) is third largest with G0471 volume of 291,566 and total Part B payments of almost $18 million in 2017. In addition, Gamma acquired the nursing home lab business of Boyce and Bynum Pathology Laboratories (Columbia, MO) in late 2018.

Top 25 Fastest-Growing Labs by Medicare Part B Volume of Services

Laboratory Economics Issues Research Report on U.S. Anatomic Pathology Market

by Jondavid Klipp | Sep 23, 2019 | Laboratory Economics, Laboratory Market Research

Laboratory Economics Issues Research Report on U.S. Anatomic Pathology Market

The publisher of Laboratory Economics has just released The U.S. Anatomic Pathology Market: Forecast & Trends 2019-2021. With this special report, you can tap into 150 pages of proprietary market research that reveals critical data and information about key business trends affecting the anatomic pathology market.

The report reveals that the anatomic pathology market (including Pap testing) now represents an estimated $18 billion of revenue with an annual growth rate of 3-4%. All data and trends are fully explained throughout the report, including 10-year historical data and a detailed three-year forecast.

The U.S. anatomic pathology market endured intense reimbursement pressure between 2013 and 2017. “However, the Medicare program has completed its evaluation of payment rates for all the key pathology codes and the reimbursement environment now appears stable,” according to Jondavid Klipp, Publisher of Laboratory Economics. “Furthermore, the introduction of new higher-priced molecular oncology tests linked to targeted cancer drugs is driving volume trends higher. As a result, the outlook for the U.S. anatomic pathology market is the best it’s been in the past 10 years.”

The report includes:

More than 100 charts and graphs
Industry size and growth rates
Detailed estimates for market subsets like prostate cancer testing, dermatopathology, lymphoma/leukemia and gastrointestinal
pathology
Medicare claims data for 60 key pathology codes
Cervical cancer testing trends and pricing data
In-office histology lab trends
Detailed analysis of the digital pathology market
Results from Laboratory Economics’ exclusive Anatomic Pathology
and Clinical Lab Trends Surveys from 2007 through 2019

Anatomic pathology companies featured in this report include: Aurora Diagnostics, Bako Diagnostics, CellNetix Labs, Exact Sciences, Genomic Health, InformDX, LabCorp/Dianon, Myriad Genetics, Mayo Clinic Labs, NeoGenomics, OPKO/BioReference Labs, PathGroup, Pathology Reference Laboratory, Poplar Healthcare, ProPath Services, Quest Diagnostics/AmeriPath and Sonic Healthcare USA.

The U.S. Anatomic Pathology Market: Forecast & Trends 2019-2021 is published by Laboratory Economics (www.laboratoryeconomics.com), an independent market research firm focused exclusively on the business of pathology and laboratory medicine.

Contact Information
Contact: Jondavid Klipp, President
Laboratory Economics
195 Kingwood Park
Poughkeepsie, NY 12601
Phone: 845-463-0080
www.laboratoryeconomics.com

Special New Year’s Report: Lab Execs Share Outlook for 2019

by Jondavid Klipp | Jan 14, 2019 | Laboratory Economics, Laboratory Market Research, Laboratory Outlook

Special New Year’s Report: Lab Execs Share Outlook for 2019

For an inside look at what may be in store for the clinical lab and pathology business this year, Laboratory Economics interviewed the top executives at a diverse group of 10 lab companies.

Not surprisingly, our interviews revealed that commercial insurers are using Medicare’s repricing of the CLFS as a pretext to cut their own rates. What is surprising (and alarming) is that some commercial insurers have demanded the full three-year phased-in ~30% CLFS reduction applied to their rates upfront immediately.

Labs are hoping to offset the pricing pressure by gaining economies of scale through geographic and test menu expansion. On the brighter side, the extreme pricing pressure that terrorized technical services for anatomic pathology seems to be over. Furthermore, molecular diagnostics and prescription drug monitoring continue to be high-growth markets.

Pricing pressure from both Medicare and commercial insurers
High volume growth in molecular diagnostics and prescription drug monitoring
Anatomic pathology reimbursement rates have stabilized
Hospital outreach labs benefiting from health system acquisitions of physician practices
Nursing home labs are restructuring and consolidating

Companies profiled in the January 2019 issue of Laboratory Economics include Sonic Healthcare USA, NeoGenomics, Health Network Laboratories, CellNetix, TriCore Reference Labs, Enzo Clinical Labs, Clinical Laboratory Services, CellMax Life, Psychemedics and Wisconsin Diagnostic Labs.